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Summary 
The available MRI diagnostic criteria in patients with multiple sclerosis (MS) need 
clarifications and modifications. Within the MAGNIMS network, a workshop was held to discuss 
the state-of-the-art MRI findings in these patients and provide an evidence-based and expert opinion 
consensus on how the diagnostic algorithm should be modified. Proposed modifications to disease 
dissemination in space (DIS) criteria include: increasing the number of lesions necessary to confirm 
the involvement of the periventricular area, from 1 to 3; adding the optic nerve as an additional 
CNS location; using the term “cortical/juxtacortical” to expand the concept of juxtacortical lesions. 
Apply identical DIS criteria for progressive- and relapse-onset MS. No distinction should be made 
between symptomatic and asymptomatic lesions. Similar MRI criteria should be applied to: a) 
children with non-ADEM-like presentation; b) Asia or Latin America populations; and c) 
radiologically isolated syndrome subjects. Lesion features distinctive of MS could emerge from the 
use of ultra-high field scanners. 
 
Key words: Multiple Sclerosis; Magnetic Resonance Imaging; Diagnosis; Criteria. 
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Introduction 
Magnetic resonance imaging (MRI) has been formally included in the diagnostic work-up of 
patients presenting with a clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) 
in 2001 by an International Panel of experts.1 MS diagnosis requires the demonstration of disease 
dissemination in space (DIS) and time (DIT) and the exclusion of other conditions that can mimic 
MS by their clinical and laboratory profile. MRI can support and substitute clinical information for 
MS diagnosis, allowing an earlier and accurate diagnosis and, consequently, earlier treatment.  
MRI criteria for MS are based on the presence of focal lesions in the white matter (WM) of 
the central nervous system (CNS), which are considered typical for this condition in terms of 
distribution, morphology, evolution and signal abnormalities on conventional MRI sequences (e.g., 
T2-weighted, T2-FLAIR, pre- and post-contrast T1-weighted scans).2-4 Several modifications of 
MRI diagnostic criteria have been proposed over the years. These revisions have simplified the 
lesion count models for demonstrating DIS, changed the timing of MRI scan for demonstrating 
DIT, and increased the value of spinal cord imaging.5-8 In 2007 the European collaborative research 
network that studies MRI in MS (MAGNIMS) has reviewed the findings of studies that addressed 
these issues and proposed new MRI criteria to be applied in MS.9 Those MAGNIMS criteria are 
currently included in the most recent of the MS diagnostic criteria, known as the 2010 McDonald 
criteria.10 Recent consensus guidelines for clinicians for the optimization of the use of brain and 
spinal cord MRI in the diagnostic process of MS (planning, performance and interpretation) have 
also been published.{Rovira, 2015 #2455}  
Since 2011, new data regarding the application of MRI for demonstrating DIS and DIT have 
become available, and these deserve consideration for future revisions of the MS criteria. 
Additionally, many improvements in MRI technology have occurred, which resulted in the 
development of innovative acquisition sequences, the identification of novel pathophysiological 
mechanisms which may help in the differential diagnosis, as well as new insights into MS disease 
activity as evidenced by high field and ultra-high field scanners. Within MAGNIMS, it was felt that 
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there is the need of a timely revision of these recent findings and how these should modify the 
diagnostic work-up of MS patients. 
 
Methods 
In March 2015, an international workshop was held in Milan, Italy, under the auspices of 
MAGNIMS. The workshop involved clinical and imaging experts in the diagnosis and management 
of patients with MS, and included physicians, neurologists and neuroradiologists. Before the 
meeting, two co-chairs (MF and FB) identified topics that were deemed to need a revision and/or a 
definition in future MS diagnostic criteria. Experts for each topic were invited to provide a 
summary during the meeting of the main findings related to their argument, based on revision of the 
literature and on their personal experience. Afterwards, they had to define whether such a measure 
was judged useful or not in the diagnostic process and whether it was promising to move the field 
forward in the future, in order to stimulate group discussion. For each measure, a group agreement 
was reached during the workshop, and summarized in a first draft, which was circulated among the 
meeting participants plus some additional experts in the field for critical discussion and revision.  
 
MRI criteria for DIS 
According to the 2010 McDonald criteria for MS,10 DIS can be demonstrated with at least 
one T2 lesion in at least 2 of 4 locations characteristic for MS (juxtacortical, periventricular, 
infratentorial, and spinal cord). We propose to increase the number of lesions necessary to confirm 
the involvement of the periventricular area, from 1 to 3, and add an additional CNS location, which 
is the optic nerve (Table 1). 
Periventricular lesions. A single lesion was deemed not sufficiently sensitive to define 
whether the involvement of the periventricular region is due to a demyelinating inflammatory event. 
Indeed, incidental periventricular lesions can be detected in healthy individuals and patients with 
other neurological conditions, including up to 30% of patients with migraine.11 The analysis of a 
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large cohort of 652 CIS patients has shown that in patients not satisfying DIS criteria for MS, the 
presence of 3 periventricular lesions, combined with age or presence of oligoclonal bands (OB), is 
helpful in identifying those at risk for MS.12 In a retrospective study in patients with spinal cord 
CIS, a prediction model, including age ≤40 years, ≥3 periventricular lesions, and immunoglobulin 
intrathecal synthesis identified with an accuracy of 78% patients evolving to MS.13 Interestingly, ≥3 
periventricular lesions was the most accurate threshold determined by receiver-operating curve 
analysis in Barkhof et al.4 and applied in previous McDonald criteria.1, 8 In a multicenter trial of 468 
CIS patients, the presence of at least 3 periventricular lesions had a strong prognostic value for 
conversion to MS over a 3 year period.{Moraal, 2009 #2457} In a study comparing patients with 
MS and those with from primary and secondary CNS vasculitis, the presence of ≥3 periventricular 
lesions was the only individual components of the Barkhof’s criteria able to distinguish MS from 
SLE/Sjogren’s patients.{Kim, 2014 #2456} 
In pediatric MS patients, however, the presence of a single periventricular lesion (as well as 
one or more T1 hypointense lesions) powerfully distinguished children with MS from children with 
monophasic demyelination.14  
Optic nerve lesions. Around 20-31% of CIS patients present with an acute optic neuritis.15-17 
Compared to other clinical presentations, adult patients with optic neuritis are more likely than 
those with acute demyelination in other CNS locations to have a monophasic illness,15, 18, 19 as also 
confirmed by a recent study that enrolled 1058 CIS patients.16 Importantly, in this cohort and in 
other studies, the likelihood of optic neuritis being a monophasic illness is dramatically reduced if 
the presence of CSF OB and/or the presence of clinically silent brain MRI lesions (with a hazard 
ratio [HR] of 5.1 for patients with one to three lesions, and 11.3 for patients with 10 or more 
lesions). The presence of even one clinically silent T2 hyperintense brain lesion in children with 
optic neuritis is highly associated with confirmation of a MS diagnosis,20 while the absence of brain 
lesions is strongly predictive of a monophasic illness.21  
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Clinical features of optic neuritis (visual impairment, scotoma, red-green desaturation, pain 
with ocular movement), MRI evidence of optic nerve inflammation (increased T2 signal, 
gadolinium enhancement or optic nerve swelling), and neurophysiological test (visual evoked 
potentials or optical coherence tomography) supports the optic nerve as an additional CNS area 
affected at CIS onset. Clinical documentation of optic nerve atrophy or pallor, neurophysiological 
confirmation of optic nerve dysfunction (slowed conduction, and retinal nerve fiber layer thinning), 
or MRI features of clinically silent optic nerve inflammation support DIS, and in patients without 
concurrent visual symptoms, also support DIT.  
Cortical lesions. Pathologic studies have shown extensive involvement of the gray matter 
(GM) in MS patients.22-24 According to their location within the GM, different cortical lesion (CL) 
locations (sub-pial, purely intracortical, and leukocortical lesions abutting the GM-WM border) 
have been identified.23 Imaging CL is challenging (particularly using conventional clinical scan 
protocols). Different MRI techniques have been proposed and are currently being compared for 
their sensitivity to CL detection, including double inversion recovery (DIR),25 phase-sensitive 
inversion recovery (PSIR)26-28 and magnetization-prepared rapid acquisition with gradient echo29 
sequences (Figure 1). Despite this, correlative MRI-pathology studies have shown that many CLs 
remain invisible on MRI, at least at 1.5 and 3.0 Tesla MRI strengths.30, 31  
Using DIR sequences, CLs have been identified in more than 30% of CIS patients.32, 33 In a 
cohort of 80 CIS patients with a 4-year follow up, the accuracy of MRI diagnostic criteria for MS 
was increased when considering the presence of at least 1 intracortical (IC) lesion on baseline 
scans.33 CL assessment may also help in the differential diagnosis between MS and mimicking-MS 
conditions, since they have not been found in patients with migraine with T2-WM lesions11 or 
neuromyelitis optica (NMO).34 IC lesions are also rare in healthy controls (1/60 subjects using PSIR 
sequences).27 
Even with these promising results, there remain many unsolved issues related to the 
inclusion of CL assessment in the diagnostic work-up of CIS patients. First, the MRI sequences 
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used in research setting for the identification of these lesions may not be available and easily 
implementable on the majority of clinical scanners. Second, the acquisition parameters for these 
sequences still need to be standardized on different manufactures and field strengths. Third, inter-
observer agreement in the assessment of these sequences is moderate (complete agreement=19% for 
DIR), and guidelines for their evaluation are evolving.27, 35 Fourth, different criteria and terms are 
currently being applied by different research groups for the distinction between IC, leukocortical, 
mixed WM/GM and juxtacortical lesions.25-28, 33 Additionally, subpial demyelination, which can be 
quite extensive, is usually not scored.24 The term “cortical/juxtacortical” is recommended to expand 
the concept of juxtacortical lesion in the DIS criteria and to include all types of MS CLs. 
  
MRI criteria for DIT 
According to the 2010 McDonald criteria,10 DIT can be demonstrated by: 1) a new T2 
and/or gadolinium-enhancing lesion(s) on follow up MRI, with reference to a baseline scan, 
irrespective of the timing of the baseline MRI, or 2) the simultaneous presence of asymptomatic 
gadolinium-enhancing and non-enhancing lesions at any time.  
 Non-enhancing T1-hypointense lesions (black holes). Non-enhancing T1-hypointense 
lesions (black holes) are chronic lesions characterized by severe axonal damage.36 In relapsing-
remitting (RR) MS, brain T1-hypointense lesion volume increases by approximately 11% per year 
and correlates with long-term disability progression.37, 38 T1-hypointense lesion formation is more 
common in patients with longer disease durations and progressive disease subtypes. For that reason, 
their presence in CIS patients is indicative of an already established MS disease process. The 
prevalence of non-enhancing T1-hypointense lesions and their added value in identifying adult 
patients with MS was analyzed in a large multicenter study of 520 CIS patients.39 Non-enhancing 
black holes were relatively common in adult CIS patients (36%) and were associated with a higher 
likelihood of MS diagnosis. However, the value of this MR finding for predicting a second clinical 
attack in these patients was last when added to the other criteria.39  Of note, T1-hypointese lesion 
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assessment is still rather subjective and highly dependent on the type of T1-weighted sequence and 
field strength. Nevertheless, in pediatric patients with acute demyelination, the presence of one or 
more T1 hypointense lesion was highly correlated with subsequent confirmation of MS.14 
 
Symptomatic lesions  
In CIS patients, the symptomatic lesions that align with the acute clinical deficit(s) do not 
contribute to the DIS or DIT component of the MS diagnostic criteria.10 Specifically, in patients 
with brainstem or spinal cord syndromes, lesions within the symptomatic region cannot be counted 
for demonstration of DIS. The simultaneous presence of asymptomatic gadolinium-enhancing and 
non-enhancing lesions at any time is a criterion to define DIT. 
In CIS patients presenting with brainstem symptoms, a 2004 study showed that the 
specificity for MRI criteria for DIS (Barkhof’s criteria at that time) was lower (61%) than that 
found in other CIS (myelitis and optic neuritis) (73%).40 A recent investigation41 assessed the 
likelihood of MS confirmation in 35/954 patients (3%) with one single symptomatic lesion of the 
brainstem or spinal cord with a follow up of almost 8 years. The HR of MS was higher for patients 
with a symptomatic lesion (HR=7.2) than for those with a single asymptomatic lesion in the same 
regions (HR=5.7) or no lesions (HR=1). Another retrospective study in 146 CIS patients who 
fulfilled the 2010 McDonald criteria10 found that the presence of a symptomatic lesion identifies 
with a high sensitivity those patients with MS.42 In a recent study of 30 CIS patients who were 
studied for a mean of 7.3 years after onset, the sensitivity/specificity/accuracy of the DIS criteria 
was 73/73/73% for the 2010 McDonald criteria, 80/73/77% when asymptomatic lesions in the 
symptomatic region were included and 87/73/80% when any lesion in the symptomatic region was 
included in DIS.{Brownlee, 2015 #2458} This suggests that including lesions in the symptomatic 
region in DIS may increase the sensitivity of MRI criteria for diagnosing MS without 
compromising specificity. 
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The diagnostic impact of allowing any gadolinium-enhancing and non-enhancing lesions 
(not only asymptomatic, but also symptomatic lesions) to count for demonstrating DIT has also 
been recently analyzed.43 Inclusion of symptomatic lesions in the DIT criteria increased the 
proportion of patients satisfying the MRI diagnostic criteria for MS to 33%, compared to 30% of 
those diagnosed without including such lesions, with three additional patients meeting the 2010 
McDonald criteria. In fact, deciding what is symptomatic or not is often very difficult. It is easier to 
apply in brainstem/spinal cord presentation but no other clinical scenario.  
 
Spinal cord imaging  
 Based on the 2010 McDonald criteria,10 clinically-silent spinal cord lesions can contribute to 
both DIS and DIT. At symptom onset, spinal cord imaging is recommended in patients with clinical 
features localized to the spinal cord to rule out alternative cord pathology (i.e., compression, spinal 
cord tumor, NMO, vasculitides, etc.) and in those with non-spinal CIS not fulfilling brain MRI for 
DIS. In this second group, whole cord imaging showed that the presence of one spinal cord lesion 
identifies patients at higher risk of MS confirmation.44 Imaging of the entire cord, using at least two 
MR sequences (e.g., T2 and STIR, T2 and DIR, T2 and post-contrast T1-weighted scan, etc.) is 
preferable to increase confidence in lesion identification, in part because approximately 40% of 
spinal cord lesions are found in the thoraco-lumbar region (Figure 2).45-47 The value of spinal cord 
imaging for DIT in patients without accrual of deficits referable to the spine is limited, since new 
clinically silent cord lesions are not frequent. 
 
Primary progressive MS 
 In the different formulations of the diagnostic criteria, the diagnosis of primary progressive 
(PP) MS has always been kept separate from that of the more common relapse-onset form of the 
disease. In 2009, there was a proposal of unification of DIS MRI criteria for PPMS and relapsing-
MS48 which was only partially integrated in the 2010 McDonald criteria.10 Indeed, according to 
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these criteria, DIS in PPMS was defined by the occurrence of two of the following three criteria: 1) 
DIS in the brain, based on the presence of at least one lesion in at least one area characteristic for 
MS (periventricular, juxtacortical or infratentorial); 2) DIS in the spinal cord, based on the presence 
of at least two lesions in the spinal cord; and 3) positive CSF examination.  
 The sensitivity of the spinal cord criteria and the utility of CSF examination has been 
retrospectively analyzed in a cohort of 95 PPMS patients.49 These authors found that if the 
requirement for two or more cord lesions was changed to one or more cord lesions (whether 
symptomatic or not), a higher number of patients would meet the spinal cord criteria for diagnosis, 
with increasing sensitivity and simplification of the criteria. Specificity of these criteria has still to 
be tested. 
 
MRI criteria in pediatric populations  
 The 2010 consensus was that the proposed MRI criteria also served for most pediatric MS 
patients. An alert was specified that the use of the 2010 McDonald criteria for MS at baseline was 
not applicable for children with encephalopathy and multifocal neurological deficits meeting 
criteria for ADEM.10 Such children have multiple lesions, some of which may enhance, yet when 
defined using international consensus criteria for ADEM, 95% of such children have a monophasic 
illness.21 The diagnosis of MS in pediatric patients manifesting initially with an ADEM-like first 
attack requires clinical and/or MRI evidence of further non-ADEM attacks and/or accrual of 
clinically-silent MRI lesions (which is not a component of ADEM). 
 Several studies have confirmed that the 2010 McDonald criteria perform better or similar to 
previous proposed pediatric MS criteria in children with non-ADEM presentations and in pediatric 
patients older than 11 years.50-55 While a study from 52 patients has suggested inclusion of spinal 
cord imaging at first attack does not increase the accuracy of the 2010 McDonald criteria,54 a 
retrospective investigation of 85 patients showed that the addition of spinal cord MRI was helpful in 
reaching DIS and DIT in 10% of the cases.51 
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MRI criteria in non-Caucasian populations  
  The 2010 McDonald criteria have been developed and mostly tested in typical adult 
Caucasian European and North American populations and their current formulation states that they 
require validation in Asian and Latin American populations.10 Between 2011 and 2015, the 
performance of MRI diagnostic criteria has been tested in Korean,56 Taiwanese,57 Argentinean 
(including a sub-analysis applied only to non-European descendants, i.e., mestizos, natives and 
zambos),58 and Russian59 CIS patients, after careful exclusion of alternative neurological conditions, 
such as NMO/NMOSD in Korean patients.56 All these studies provided evidence that the 2010 
McDonald criteria apply well irrespective of world region.  
 
Radiologically isolated syndromes (RIS) 
The availability of MRI evaluation for indications unrelated to MS has led to an increased 
recognition of individuals with incidental brain lesions consistent with MS. Criteria have been 
proposed to identify imaging features that may be suggestive of a clinically asymptomatic 
demyelinating condition, including the fulfillment of at least three of four Barkhof criteria for 
DIS.60, 61 The 2010 McDonald criteria concluded that “a firm diagnosis of MS based on incidental 
findings on MRI alone, even with additional supportive findings on evoked potentials or typical 
CSF findings in the absence of MS-relevant clinical symptoms, is problematic.” A conservative 
approach was proposed, stating that persons cannot be diagnosed with MS based on MRI alone, and 
that at least one clinical event consistent with acute demyelination remains a cornerstone for MS 
diagnosis. 
The use of advanced MRI techniques to characterize CNS involvement in RIS subjects has 
shown extensive axonal damage (measured using MR spectroscopy)62 and a quite high percentage 
(40%) of subjects with CLs (which were more frequent in subjects with CSF OB, cervical cord 
lesions, and DIT on brain MRI).63  
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Approximately two-thirds of RIS subjects develop new lesions on longitudinal MRI scans 
and one-third of people with RIS develop neurological symptoms within five years, especially those 
with gadolinium-enhancing or spinal cord lesions.64 In persons with clinically silent brain lesions 
consistent with MS, the presence of OBs, younger age, male sex, and abnormal visual evoked 
potentials identify individuals more likely to experience a sentinel clinical attack. Just focusing on 
MRI, the presence of gadolinium-enhancing lesions65 and of asymptomatic spinal cord lesions 
(cervical or thoracic) are predictors of clinical evolution.64, 66 
At present, there is the need for a more specific characterization of people with RIS and of 
prospective long-term studies to estimate the risk for these subjects to become MS. As a 
consequence, a firm recommendation concerning RIS is not possible. It is clear, however, even at 
this stage, that individuals bearing several risk factors need to be distinguished from those without 
these factors, since they are likely to have a prodromal condition, and that specific requirements are 
needed for a prompt diagnosis when the first symptom of CNS involvement occurs.  
 
MRI in differential diagnosis (including atypical demyelination and NMO)  
The exclusion of alternative diagnoses that can mimic MS is imperative in applying the 
2010 McDonald criteria.10 From an imaging perspective, many inherited and acquired disorders 
may manifest with evidence of DIT, DIS, or both and these should be included in the differential 
diagnosis of MS-like lesions. A timely recognition of imaging “red flags” in the work-up of patients 
suspected of having MS should alert clinicians to reconsider the differential diagnosis more 
extensively and perform some additional analyses.67 Several reviews have been published on 
imaging features of the main acquired and inherited conditions that can enter the differential 
diagnosis of MS.67-69  
In the 2010 McDonald criteria, a specific focus was the differential diagnosis between MS 
and NMO and NMO spectrum disorders (NMOSD). Up to 70% of NMOSD patients at onset have 
brain MRI lesions. The brain, optic nerve and spinal cord MRI findings of NMOSD patients have 
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been recently reviewed,70 and revised diagnostic criteria for NMOSD have been proposed.71 The 
International Panel for NMO diagnosis proposed the use of the unifying term NMOSD, which was 
stratified further by aquaporin-4 immunoglobulin G antibody (AQP4-IgG) testing. According to 
this revision, for patients with a positive AQP4-IgG test, at least one core clinical characteristic is 
required for NMOSD diagnosis; these include clinical syndromes or MRI findings related to optic 
nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. For 
AQP4-IgG negative patients or patients with unknown AQP4-IgG status, more stringent clinical 
criteria, with additional neuroimaging findings, are required. In particular, acute optic neuritis 
requires brain MRI showing (1) normal findings or only nonspecific WM lesions, or (2) optic nerve 
MRI with a T2-hyperintense or T1-weighted gadolinium-enhancing lesion extending over 1/2 the 
optic nerve length or involving the optic chiasm. Acute myelitis requires an associated 
intramedullary MRI lesion extending over 3 contiguous segments (longitudinally extensive 
transverse myelitis-LETM) or 3 contiguous segments of focal spinal cord atrophy in patients with a 
history compatible with acute myelitis. The area postrema syndrome requires associated dorsal 
medulla/area postrema lesions. Finally, an acute brainstem syndrome requires associated peri-
ependymal brainstem lesions.  
 
High field and ultra-high field scanners  
 High field scanners (3.0 Tesla). Compared to 1.5 Tesla, the use of high field strength 
scanners (3.0) allows detection of a significantly higher number of lesions in CIS patients,72, 73 with 
improved recognition of lesions involving the cortex,74 infratentorial and periventricular regions.72 
The comparison of MRI criteria performance at 1.5 vs 3.0 Tesla in 40 CIS patients showed that one 
additional patient was diagnosed with DIS at high-field, without improvement for DIT.75 
 Ultra-high field scanners (7.0 Tesla). Ultra-high field MRI allows detection of a significant 
higher number of lesions,76 better definition of lesions located in the WM and GM, their 
morphology and their association with the vasculature77-81 at a resolution closer to that of histo-
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pathological assessment than what was previously shown by using 1.582 or 3.083 Tesla scanners. 
Whether the assessment of lesion number and distribution using ultra-high field MRI scanners 
assists in making an earlier diagnosis of MS in CIS patients has not yet been evaluated. Several 
studies have identified some interesting lesion characteristics, which can aid the differential 
diagnosis between MS and other neurological conditions. The better definition of the relationship 
between demyelinating lesions and the intraparenchymal venous system, obtained by using T2*-
weighted magnitude and phase imaging confirms pathological studies demonstrating that many MS 
plaques form around the microvasculature.77-81, 84, 85 The perivenular lesion location can help to 
distinguish WM lesions in MS patients from incidental (ischemic) WM lesions.81, 85 This finding 
has been reinforced by investigation of blood-brain barrier abnormalities in MS at 7 Tesla, which 
showed that the majority of enhancing lesions are perivenular and that the smallest lesions have a 
concentric pattern of enhancement, suggesting that they grow outward from a central vein.86, 87 The 
presence of a central small vein and a rim of hypointensity on 7 Tesla T2*-weighted magnitude or 
FLAIR*81 could be a distinctive feature of MS WM lesions, which may assist in the differentiation 
from lesions of patients with NMOSD88 or Susac syndrome.89  
A limited number of studies has tracked the longitudinal evolution of the previous 
abnormalities (Figure 3). A longitudinal study of 29 patients with possible but unclear diagnosis has 
shown the presence of a central vein in most lesions to accurately identify MS patients.76 Another 
study has shown that ring phase lesions remained unchanged over a 2.5 year period in five RRMS 
patients,90 whereas such a ring can be transient in acute lesions.86, 87 
 
Summary  
The Panel presents a synthesis of the main revisions or clarifications to the MRI component 
of the 2010 McDonald criteria for MS we propose.  
There is evidence of some promising measures, which deserve further investigations before 
being moved (or not) to diagnostic criteria in the future: 
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- Identification of the central vein. What remains to be done is the standardization of 
sequences capable of showing these features on 3.0 and 1.5 Tesla scanners and creation 
of standardized definitions for identification of central veins. At present, centralized 
veins were counted if they 1) could be visualized in at least 2 perpendicular planes, 2) 
appeared linear in at least one plane, and 3) were completely surrounded by hyperintense 
signal in at least one plane (Figure 4).85 Whether central veins are indeed confirmatory 
for MS lesions requires further study with appropriate disease comparisons. 
- Identification of the hypointense lesional rim (on T2*-weighted magnitude and/or phase 
imaging images). What remains to be done is the performance of longitudinal studies (at 
both 3.0 and 7 Tesla); the clinical implementation and standardization of MR sequences 
among different vendors (at 3.0 Tesla); the analysis of the value in predicting conversion 
to MS and disability progression in CIS patients; the study of different MS disease 
clinical phenotypes and other neurological conditions, that can mimic MS. 
- Identification of cortical pathology. Higher field strength imaging will identify CLs more 
reliably than conventional MRI, but is not likely to be available in clinical practice. More 
advanced techniques for CL identification at 3.0 Tesla may prove valuable in MS 
diagnosis. The definition of standardized guidelines for CL classification is also pending.   
 
Closing remarks 
Reading of MRI scans should be done in the appropriate clinical context. The premise of 
these guidelines and criteria is that we assume a basic knowledge of what constitutes a lesion. The 
largest linear measurement for lesion definition should be > 3 mm in at least one plane of 
acquisition. Therefore, lesion identification should be done by expert and trained personnel. Image 
quality must be of high standard. A conservative approach in identifying lesions should be adopted.  
In the diagnostic work up of patients with a suspicious of MS, the use of post-contrast 
sequences provides important pieces of information for the differential diagnosis. However, the 
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Food and Drug Administration (FDA) has recently made a safety communication for the long term 
effects of repeated gadolinium-based contrast agents (GBCAs), following the description of 
deposits of GBCAs in the brains of some patients who undergo four or more contrast MRI scans, 
long after the last administration 
(http://www.fda.gov/downloads/Drugs/DrugSafety/UCM455390.pdf). 
MRI remains a valuable tool in identification of children and adults with MS- both at the 
time of an incident attack and when applied serially to confirm the chronic nature of this disease. 
More advanced imaging techniques inform on regional CNS involvement with greater sensitivity, 
and may add to diagnostic specificity. Whether MRI features consistent with MS in the absence of 
clinical involvement can confirm MS diagnosis remains an area of controversy that requires further 
deliberation, particularly given evidence that some such individuals demonstrate focal and global 
loss of tissue integrity yet are not currently eligible for MS-directed therapies. As higher strength 
imaging and newer sequences better approximate pathology-level interrogation of the CNS, the 
fundamental question of what defines a disease like MS will need to be answered.  
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Search strategy and selection criteria 
References for this Review were identified through searches of PubMed with the search terms 
“Clinically Isolated Syndrome”, “Multiple Sclerosis”, “McDonald criteria”, “Diagnosis”, 
“Differential diagnosis”, “Cortical Lesions”, “White matter”, “Lesions”, “Cortical Lesions”, 
“Brain”, “Spinal Cord”, “MRI”, “Optic Nerve”; “Disease Dissemination in Spce”; “Disease 
Dissemination in Time”; “Radiologically Isolated Syndromes”; “Pediatric MS”; “T1-hypointense 
lesions”; “Symptomatic Lesions”, “Primary Progressive Multiple Sclerosis”; “Non-Caucasian 
Populations”; “Neuromyelitis Optica”; “Neuromyelitis Optica Spectrum Disorders”; “High Field”; 
and “Utra-high field” from 1979 until July 2015. Articles were also identified through searches of 
the authors’ own files. Only papers published in English were reviewed. The final reference list was 
generated on the basis of originality and relevance to the broad scope of this Review. 
 
Acknowledgements 
We are eagerly grateful to Douglas Arnold (Brain Imaging Center, Montreal Neurological 
Institute, McGill University, Montreal, Quebec, Canada) for his fruitful discussion during the 
meeting and his comments and revision of the manuscript.  
Sponsors- This course was supported by an unrestricted education grant from Novartis. 
  
18 
 
Conflict of interest statement 
M. Filippi is Editor-in-Chief of the Journal of Neurology; serves on scientific advisory boards for 
Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking 
activities from Biogen Idec, Excemed, Novartis, and Teva Pharmaceutical Industries; and receives 
research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of 
Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer's Drug Discovery Foundation 
(ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione 
Italiana di Ricerca per la SLA). 
M.A. Rocca received speakers honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis and 
Excemed and receives research support from the Italian Ministry of Health and Fondazione Italiana 
Sclerosi Multipla. 
O. Ciccarelli serves as a consultant for GE, Biogen and Novartis and all the payments are made to 
the institution. She receives research support from the Multiple Sclerosis Society of Great Britain 
and Northern Ireland, the Department of Health Comprehensive Biomedical Centre, and the 
Engineering and Physical Sciences Research Council (EPSRC).  
N. De Stefano has received honoraria from Schering, Biogen-Idec, Teva, Novartis, Genzyme, and 
Merck Serono S.A. for consulting services, speaking and travel support. He serves on advisory 
boards for, Biogen-Idec Merck Serono S.A and Novartis. 
N. Evangelou has received honoraria from Biogen, Novartis and Genzyme for consulting services, 
speaking and travel support. He serves on advisory boards for Biogen, Merck, and Novartis. He 
receives research support from the MRC and the MS Society of Great Britain and Northern Ireland. 
L. Kappos' Institution (University Hospital Basel) received in the last 3 years and used exclusively 
for research support: steering committee, advisory board and consultancy fees (Actelion, Addex, 
Bayer Health Care, Biogen, Biotica, Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, 
Pfizer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva, UCB, Xenoport); speaker fees (Bayer 
Health Care, Biogen, Merck, Novartis, Sanofi-Aventis, Teva ); support of educational activities 
(Bayer Health Care, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi, Teva); royalties 
(Neurostatus Systems GmbH); grants (Bayer Health Care, Biogen, Merck, Novartis, Roche, Swiss 
MS Society, the Swiss National Research Foundation, the European Union, Roche Research 
Foundations). 
A. Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA 
Medical, has received speaker honoraria from Bayer, Genzyme, Bracco, Merck-Serono, Teva 
Pharmaceutical Industries Ltd, OLEA Medical, Stendhal, Novartis and Biogen Idec, and has 
research agreements with Siemens AG. 
19 
 
J. Sastre-Garriga has received compensation for serving on scientific advisory boards or in 
speaker’s bureaus from Biogen, Merck-Serono, Novartis, Teva and Sanofi-Aventis. He serves in the 
editorial board of Multiple Sclerosis Journal. 
M. Tintorè has received compensation for consulting services and speaking from Bayer-Schering, 
Merck-Serono, Biogen-Idec, Teva, Sanofi-Aventis, and Novartis. 
J.L. Frederiksen has served on scientific advisory boards for and received funding of travel for these 
activities and honoraria from Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, 
Takeda and Teva; and has received speaker honoraria from Biogen Idec and Merck Serono. 
C. Gasperini has received compensation for consulting from Bayer HealthCare and Biogen and as a 
speaker for lectures from Biogen, Bayer HealthCare, Genzyme, Merck Serono, Novartis and Teva. 
J. Palace reports personal fees from Biogen Idec, personal fees from Teva Pharmaceuticals and an 
unrestricted research grant, personal fees from Merck Serono, grants from Merck Serono, personal 
fees from Bayer Schering, grants from Bayer Schering, personal fees from Novartis, grants from 
Novartis, personal fees from Chugai Pharma, personal fees from Ono Pharmaceuticals Co Ltd, 
personal fees from CI consulting, grants from MSS UK, grants from Guthy-Jackson Foundation, 
outside the submitted work. 
D. Reich’s research is supported by the Intramural Research Program of the National Institute of 
Neurological Disorders and Stroke, and he has received additional research support from the Myelin 
Repair Foundation and Vertex Pharmaceuticals. 
B. Banwell serves as a centralized MRI reviewer for Novartis, and serves as an unpaid advisor 
regarding pediatric MS clinical trial design for Novartis, Biogen Idec, and Tevaneuroscience.  
X. Montalban has received speaking honoraria and travel expenses for scientific meetings, has been 
a steering committee member of clinical trials or participated in advisory boards of clinical trials in 
the past years with Bayer Schering Pharma, Biogen-Idec, EMD Merck-Serono, Genentech, 
Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals and Almirall. 
F. Barkhof serves as a scientific consultant to Bayer-Schering, Sanofi-Aventis, Synthon, Novartis, 
Biogen-IDEC, Merck-Serono, Toshiba Medical systems, Roche, Janssen, TEVA, and Genzyme; 
serves as an editorial board member for Brain, European Radiology, Multiple Sclerosis Journal, 
Neuroradiology, Radiology, and Neurology; serves as a consultant for Sanofi-Aventis, Synthon, 
Janssen, Novartis, Biogen-Idec, Roche, and TEVA; has served on speakers' bureaus for Novartis 
and Biogen; and receives research support from Neugrid4you (FP7 European committee) and Dutch 
Foundation for MS Research—centre grant 2010–2014. 
 
20 
 
Authors’ contribution. MF and FB had the idea of organizing the meeting, chaired it, and framed 
the structure of this manuscript. AR, FB, JSG, LK, MAR, MT, NDS, NE and OC participated to the 
meeting, summarized different aspects for the discussion and took part to the discussion. JF, CG, JP 
and DRS participated to the meeting and the discussion. BB and XM were involved after the 
meeting for critical discussion and revision. The complete manuscript was commented, revised and 
approved also by all authors. 
 
  
21 
 
 
Table 1. Proposed 2015 MAGNIMS DIS criteria 
DIS can be demonstrated by the involvement* of at least 2 out of 5 areas of the CNS as 
follows: 
≥ 3 periventricular lesions 
≥ 1 infratentorial lesion 
≥ 1 spinal cord lesion 
≥ 1 optic nerve lesion 
≥ 1 lesion involving the cortex  
*If a subject has a brainstem or spinal cord syndrome, or optic neuritis, the symptomatic lesion(s) 
are not excluded from the criteria and contribute to lesion count.  
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Figure legends 
 
Figure 1. Examples of lesion classification based on integrated analysis of double inversion 
recovery (DIR) and magnetization-prepared rapid acquisition with gradient echo (MPRAGE) 
sequences. Top row: a hyperintense lesion close to the cortex is visible on DIR sequence (white 
arrow). MPRAGE sequence shows the location in the white matter of such a lesion. Middle row:  
a hyperintense lesion close to the cortex is visible on DIR sequence (white arrow). MPRAGE 
sequence shows the location close to the cortex (juxtacortical) of such a lesion. Bottom row: a 
hyperintense lesion close to the cortex is visible on DIR sequence (white arrow). MPRAGE 
sequence shows the intracortical location of such a lesion. 
 
Figure 2. Spinal cord lesions from Fred 
 
Figure 3. 7 T longitudinal lesions from Daniel 
 
Figure 4. Pre-contrast 3T FLAIR* images (axial, sagittal and coronal views) of a 33-year-old 
woman with MS. A conspicuous central vein is clearly visible in the majority of hyperintense 
lesions. The definition of “perivenular” lesion requires the visualization of the central vein in at 
least two perpendicular views (arrows in magnified boxes). 
 
 
 
 
